Progression-free survival (PFS) of GIST patients was significantly worse in patients with KIT exon 9 mutations than in those with KIT exon 11 mutations, OR was 3.60, 95% CI 2.17–5.98, z = 4.96, p < 0.00001, heterogeneity I2 = 0% (Fig. 4). The gene discussed is KIT; the disease is gastrointestinal stromal tumor.